
Last updated: 2026-09-26 10:34:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alector, Inc. (ALEC) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.95, with a market capitalization of $214.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.09 to $3.40. This page covers its latest market performance, valuation, price trends and company information.
$214.38M | |
$1.92 | |
$43.32 | |
$0.87 | |
$1.92 | |
964.77K | |
1.15M | |
-- | |
$3.40 | |
$1.09 | |
-- | |
-- |
Alector, Inc. (ALEC) last closed at $1.92 as of 2026-09-25 23:47:00, unchanged from the previous close of $1.92.
During the latest regular trading session, ALEC traded between $0.87 and $43.32, with a volume of 964.77K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Alector, Inc. (ALEC) moved from $1.85 to $1.95, representing a gain of 5.35% ($0.10).
The stock traded between $1.79 and $2.05 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.26 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.2%
ALEC is currently trading at $1.95, placing it 37.2% of the way from its 52-week low of $1.09 to its 52-week high of $3.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alector, Inc. (ALEC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.